key: cord-0905306-lnrttc2s
authors: Takeshita, Masaru; Nishina, Naoshi; Moriyama, Saya; Takahashi, Yoshimasa; Uwamino, Yoshifumi; Nagata, Mika; Aoki, Wataru; Masaki, Katsunori; Ishii, Makoto; Saya, Hideyuki; Kondo, Yasushi; Kaneko, Yuko; Suzuki, Katsuya; Fukunaga, Koichi; Takeuchi, Tsutomu
title: Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan
date: 2021-01-06
journal: Virology
DOI: 10.1016/j.virol.2020.12.020
sha: 71d2950419aaf2da399206b25f9e1b4bd8639d2a
doc_id: 905306
cord_uid: lnrttc2s

The pandemic of COVID-19 is still ongoing, and many studies on serum antibodies have been reported, however, there are few studies about asymptomatic and mild patients. In this study, we enrolled 44 COVID-19 patients with relatively mild disease and 48 pre-pandemic controls. We measured serum antibodies against extracellular domain, S1 domain, and receptor-binding domain of Spike and N protein, examined neutralization titers by authentic virus neutralization assay and newly-developed bead/cell-based Spike-ACE2 inhibition assay, and compared them with clinical features. Most of these antibodies, including neutralizing titers, were mutually correlated, and the production of antibodies were associated with low Ct values of PCR test, disease severity, symptoms especially pneumonia, lymphopenia, and serological test including CRP, LD, D-dimer, and procalcitonin. Notably, 87.5% of asymptomatic and 23.5% of mild patients did not have antibody against SARS-CoV-2. Our results revealed the inadequate acquisition of humoral immunity in patients with asymptomatic and mild COVID-19 patients.

Although the SARS-CoV-2 pandemic continues worldwide, in some countries, especially those in East Asia, the number of patients tends to be lower than in other areas. Several hypotheses, such as the difference in genetic backgrounds, socio-behavioral differences, mutations in SARS-CoV-2 genomes, and the possibility of having cross-reactive immunity to similar viruses, are inferred as causes of this difference but has not been identified [1] [2] [3] . In Japan, the number of infected patients has started to increase; however, massive outbreaks have been avoided without using forced policies.

Antibody titers against various SARS-CoV-2-derived antigens have been measured and reported to have high specificity for the Spike protein and Nucleocapsid protein (N) [4] , and many of the antibody tests have been developed using Spike and/or N as antigens. The serum antibody titers were reported to rise from 10-14 days after onset and peak at the third week [5] [6] [7] [8] [9] . To measure the neutralizing titer, several procedures using live virus or pseudovirus have been developed, and it is also known that the titer of neutralizing antibody correlates to some extent with the antibodies against Spike and the N protein [10] [11] [12] [13] . In Japan, although two groups reported that seroconversion was observed in 87% and 96% of patients using a lateral flow kit two weeks after onset [14, 15] , there are few detailed studies about the association between serum antibodies and clinical parameters.

Our hospital has cared for various patients, including those with symptoms from asymptomatic to severe, and reported their clinical symptoms [16] . In this study, we aimed to investigate their serological features. Here, we established a bead-based assay for measuring serum antibodies against Spike-derived proteins and N, and bead-based and cell-based procedures for examining the serum Spike-ACE2 inhibition rate, in addition to authentic virus neutralization assay. This study reported the humoral immune responses in Japanese patients with relatively mild disease and their association with detailed clinical features.

Patients were recruited at Keio University Hospital from April to July 2020. PCR tests were performed on admission and once every 3-5 days thereafter. Serum samples from patients were collected at discharge or at the first outpatient visit. Serum samples from healthy controls were collected and preserved before November 2019. The following parameters were collected from medical charts: signs and symptoms; neutrophil and lymphocyte counts; serum parameters of lactate dehydrogenase (LD), C-reactive protein (CRP), ferritin, D-dimer, procalcitonin, sialylated carbohydrate antigen KL-6, and estimated glomerular filtration rate (eGFR); and medication history. The pneumonia was diagnosed based on the lung CT. This study was approved by the The antibodies against SECD, S1, RBD, and N were measured by antigen-binding bead assays as previously described [18] . In detail, 20μl of Dynabeads M280 streptavidin (Thermo) were incubated with 4 μg of RBD-SBP, 16 μg of S1-SBP, 32 μg of SECD-SBP, or 10 μg of N-SBP in 100 μl of TBSTx overnight at 4°C with shaking. After washing with PBS with 0.05% Tween-20 (PBS-T), RBD-, S1-, SECD-, and N-binding beads were transferred into 96 well plate and incubated with 50 Bead-based Spike-ACE2 inhibition assay RBD-binding beads were prepared as described above, and were incubated with 1:20-, 1:100-, or 1:500-diluted serum for 20 min at 4°C, washed, incubated with ACE2-FLAG for 20 min at 4°C, J o u r n a l P r e -p r o o f washed, and incubated with an anti-DYKDDDDK antibody for 20 min at 4°C. After the final wash, the beads were analyzed by a FACS Verse. The MFI of beads incubated without serum was used as a negative control (0% inhibition), and beads incubated without ACE2-FLAG were used as a positive control (100% inhibition). The inhibition rate was calculated as follows: inhibition rate = 1 -(MFI of sample -MFI of negative control)/(MFI of positive control -MFI of negative control).

The expression vectors (12 μg of full-length spike protein and 6 μg of pMX-GFP) were cotransfected into 293T cells on 100 mm dish using 43.2 μg of Polyethylenimine Max (Polyscience, PA, USA). After two days, cells were washed with PBS supplemented with 0.5% BSA and 2 mM EDTA (staining buffer), incubated with diluted serum samples for 20 min at 4°C, washed again, and incubated with premixed ACE2-SBP and APC-conjugated streptavidin (0.6 μg/ml and 0.4 μg/ml, respectively) for 20 min at 4°C. After the final wash, the cells were analyzed by a FACS Verse. The MFI among GFP + cells was calculated using FlowJo (BD) and used as an indicator of Spike-ACE2 binding. Cells without serum and without ACE2-SBP were used as negative and positive controls, respectively. The measurement procedures are illustrated in Heat-inactivated sera were serially diluted with Dulbecco modified Eagle medium (FUJIFILM Wako) supplemented with 2% fetal bovine serum (Biowest, Nuaillé, France) and 100 unit/ml penicillin, 100 μg/ml streptomycin (Thermo). Diluted sera were mixed with 100 TCID50 SARS-CoV-2 JPN/TY/WK-521 strain [19] and incubated at 37°C for 1 hour. The mixtures were placed on VeroE6/TMRRSS2 cells (JCRB1819, JCRB Cell Bank, Osaka, Japan) and cultured for 5 days at 37°C with 5% CO2. For the evaluation of cytopathic effect (CPE), plates were fixed with 20% formalin (FUJIFILM Wako) and stained with crystal violet solution (Sigma-Aldrich, MO, USA).

The highest sera dilution factor with 100% CPE inhibition was defined as authentic virus neutralization titer.

The following antibodies were used: anti-human IgG-Fc (APC, goat-F(ab') 2 fragment), anti-human IgM-Fc (APC, goat-F(ab') 2 fragment), and anti-human IgA-Fc (APC, goat-F(ab') 2 fragment) from Jackson ImmunoResearch (PA, USA); anti-human IgG1 hinge (AF647, 4E3), anti-human IgG2-Fc (AF647, HP6002), anti-human IgG3 hinge (AF647, HP6050), and anti-human IgG4-Fc (AF647, HP6025) from Southern Biotech (AL, USA); and anti-DYKDDDDK antibody (AF647, FLA1) from MBL (Nagoya, Japan).

Statistics Continuous data are presented as the median and interquartile range (IQR) or as a number with the percentage value, as appropriate. The chi-squared test was used to examine the categorical variables, and the Wilcoxon rank sum test was used to examine the continuous variables.

Correlations between two continuous variables were analyzed using Spearman's rank correlation coefficient. A model for the authentic virus neutralization titer was made using multiple linear regression analysis. The variables that were associated with the neutralizing titer, other than highest LD level and lowest lymphocyte count, which vary even in healthy subjects, were entered into the model using forward selection with a threshold p-value of 0.05. P-value < 0.05 were considered to be statistically significant. All statistical analyses were performed with JMP 15 (SAS Institute, NC, USA).

Our hospital experienced nosocomial infections from asymptomatic patients in April 2020 and started to perform PCR tests extensively on potentially infected personnel. Therefore, we found and treated many patients who had mild or no symptoms but were positive on PCR for J o u r n a l P r e -p r o o f SARS-CoV-2, in addition to patients who had symptoms and were diagnosed with COVID-19.

Because antibodies against SARS-CoV-2 have been reported to appear 10-14 days after onset and most seroconversion develops by the third week, we mainly collected serum samples cross-sectionally three weeks after the positive PCR test. The characteristics of participants are shown in Table 1 .

Serum antibodies against SECD, S1, RBD, and N We first measured the serum antibodies against SECD, S1, RBD, and N for each isotype. As shown in Figure 2A , some of the patients had antibodies against each antigen, while healthy individuals rarely responded to any antigen. Among the three isotypes, IgG was most clearly separated into positive and negative results, followed by IgA and IgM, and among the four tested antigens, the results for the SECD and S1 were most clearly separated. IgA and IgM against N were less positive than others in the patient group. The overall positive rate is shown in Figure 2B , which was significantly lower than the reported 80-100% [5] [6] [7] [8] [9] . We also checked IgG subclass against these antigens using 10 representative serum samples. As shown in Figure 2C , IgG1 was the most abundant for all antigens, followed by IgG2, IgG3, and IgG4.

Next, we examined the correlation of the amount of antibodies against each antigen and each isotype. As shown in Figure 3A , the antibodies against SECD and S1 had the strongest J o u r n a l P r e -p r o o f correlation between each isotype, followed by RBD and N. The correlation of antibodies against various antigens was high for IgG, followed by for IgA and IgM, as shown in Figure 3B . High correlations were observed among the Spike-derived antigens (SECD, S1, and RBD) for all isotypes, whereas some variations were shown between the antibodies against Spike-derived antigens and antibodies against N.

Next, we measured the serum antibodies that inhibit binding of Spike and ACE2 by two procedures. We prepared full-length spike-expressing cells and RBD-binding beads and incubated them with 20-fold-, 100-fold-, or 500-fold-diluted serum to examine how much subsequent binding of soluble ACE2 could be inhibited. As shown in Figure 4A , a concentration-dependent inhibition effect was observed with sera from patients but not with most of the control serum. Only one sample from healthy control reacted weakly with RBD beads.

Although the IC50 is often used as an index of the these measurements, there were many samples that did not reach 50% inhibition even with a 20-fold dilution in our cohort, so we used the inhibition rate at a 20-fold dilution as an index. In addition to these, to directly measure the virus neutralizing ability of serum, a neutralization test using authentic SARS-CoV-2 was performed for all patients' samples and some healthy control samples ( Figure 4B ). The neutralizing titers could We next compared the results of Spike-ACE2 inhibition assay and authentic virus neutralization assay. As shown in Figure 4C , the inhibition rates of both procedures were highly correlated with the authentic virus neutralization titers, and in addition, the results of the two inhibition assays were also highly correlated ( Figure 4D ). These multiple measurements confirmed that our cohort included patients with no serum neutralizing antibodies against SARS-CoV-2. Next, we examined the relationships between the serum antibodies against Spike-derived proteins and authentic virus neutralization titers. As expected, the neutralizing titer strongly correlated with the antibodies against Spike-derived proteins ( Figure 4E ). These results means that about half of the patients in this study did not have serum antibodies to SARS-CoV-2.

Finally, we examined the relationship between serum antibodies and clinical information/parameters to investigate what factors influence the production of antibodies. Figure 5 shows correlations between clinical features and authentic virus neutralization titers. Many parameters including Lowest PCR Ct value, disease severity, pneumonia, lymphocytopenia, highest CRP level, and highest D-dimer level were clearly and significantly correlated with neutralizing titers, and notably, neutralizing titers were undetectable among 15/16 (93.8%) of asymptomatic patients and 6/17 (35.3%) of mild patients. Together with the results of serum antibodies against Spike and N, 87.5% of asymptomatic patients and 23.5% of mild patients did not have any antibody against SARS-CoV-2.

To examine which of these factors had a strong effect on acquisition of humoral immunity, we next performed multiple linear regression analysis. As shown in Table 2 , three variables, highest CRP level, existence of pneumonia, and lowest PCR Ct value, had statistically significant effects on neutralizing titer with an adjusted R 2 of 0.90.

In this study, we examined the serum antibodies in Japanese COVID-19 patients with relatively mild severities. In our cohort, the amount of antibodies against viral proteins, Spike-ACE2 inhibition rates, and authentic virus neutralization titers were mutually correlated. The production of antibodies was associated with clinical symptoms such as severity and pneumonia, low PCR Ct values, lymphopenia, and serological test results including CRP, LD, D-dimer, and procalcitonin levels. Multiple linear regression analysis showed that highest CRP level, existence of pneumonia, and lowest PCR Ct value had a strong effect on neutralizing titer. We also revealed that approximately 87.5% of asymptomatic patients and 23.5% of mild patients did not acquire J o u r n a l P r e -p r o o f humoral immunity. Our results suggest that careful consideration should be applied when conducting epidemiological studies using sera.

Many previous studies reported a cohort that was more symptomatic and severe than our cohort, with 80-100% antibody prevalence three weeks after onset [11] [20] . Even in a study with mild cases in China, neutralizing antibodies were detected in 94% of patients [10] . These antibodies were reported to correlate with age, sex, presence of symptoms, severity, lymphopenia, and serum CRP levels [10, 11, 21] ; however, the prevalence of antibodies was much lower in our results. This difference is considered to be due to the many asymptomatic patients who do not have any antibody. Although there are few studies including many asymptomatic individuals, a German report [5] examining asymptomatic patients with a positive PCR test showed that 85% of these patients were antibody negative, and seropositivity were negatively correlated to Ct values, consistent with our results. These results indicate that a high viral load, pneumonia, and strong systemic response have important roles in the antibody production, similar to findings in Japan and Western countries. One problem is what happens in asymptomatic or mild patients without humoral immunity. Because PCR is repetitively positive in most patients, it is certain that the virus had existed these patients. Recently, T cell responses were reported to be observed in some antibody-negative patients [22] . How the immune reaction occurs in such patients and whether such patients are at high risk of reinfection is an important issue for future studies. 

SARS-CoV-2 infections and COVID-19 mortalities strongly correlate with ACE1 I/D genotype

Pre-existing and <em>de novo</em> humoral immunity to SARS-CoV-2 in humans, bioRxiv

Phylogenetic network analysis of SARS

Proceedings of the National Academy of Sciences of the United States of America

SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses

SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons

Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2

Evaluation of an electrochemiluminescent SARS-CoV-2 antibody assay

Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome

Clinical Validity of Serum Antibodies to SARS-CoV-2: A Case-Control Study

Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

Clinical validation of an immunochromatographic SARS-Cov-2 IgM/IgG antibody assay with Japanese cohort

Clinical evaluation of an immunochromatographic

IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19

Acute Onset Olfactory/Taste Disorders are Associated with a High Viral Burden in Mild or Asymptomatic SARS-CoV

Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV-2019) in Japan

Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Virological assessment of hospitalized patients with COVID-2019

Analysis of the diagnostic value of serum specific antibody testing for coronavirus disease

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19